Do GLP-1s affect fertility
Approval for Cardiovascular Risk Reduction Ongoing cardiovascular outcomes trials (CVOT) studies clearly demonstrated that three of the diabetes incretin medications (liraglutide, dulaglutide and semaglutide) and one of the weight loss versions of this class (Wegovy) also reduce cardiovascular disease risk
Recently, it has also been approved in certain regions for chronic weight management in adults
Dont let Ozempic teeth catch you off guardbe proactive, stay informed, and maintain regular dental care
Preferred continuous glucose monitors (CGMs) FreeStyle Libre 2, FreeStyle Libre 3, Dexcom G6, and Dexcom G7 are the preferred continuous glucose monitors when submitted through the pharmacy benefit manager (PBM) and are covered at a 10% cost-sharing
Our program includes both oral and injectable medications to support your weight loss journey